Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA7 | P43166 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263628 | 0.83 | TSHR (0.52) | KMT2AMEN1TSHRALDH1A1CA12 | |
| SCHEMBL161443 | 0.81 | KMT2A (0.50) | KMT2AMEN1TSHRALDH1A1CA12 | |
| SCHEMBL3376695 | 0.81 | KDM4E (0.51) | KMT2AMEN1TSHRALDH1A1CA12 | |
| SCHEMBL3356162 | 0.80 | KMT2A (0.49) | KMT2AMEN1TSHRALDH1A1CA12 | |
| SCHEMBL370881 | 0.80 | KMT2A (0.49) | KMT2AMEN1TSHRALDH1A1CA12 | |
| SCHEMBL23824155 | 0.80 | KMT2A (0.49) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL416936 | 0.80 | KMT2A (0.49) | KMT2AMEN1TSHRALDH1A1CA12 | |
| SCHEMBL309808 | 0.80 | ALDH1A1 (0.54) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL3261638 | 0.79 | TSHR (0.52) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL3721899 | 0.79 | TSHR (0.52) | KMT2AMEN1TSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283778-A | Pyrazolecarboxylic acid compound as well as preparation method and application thereof | 江苏理工学院 | 2023-06-23 | — | — | CN | claimed |
| CN-111057006-B | Preparation method of 1- (4-chlorphenyl) -3-pyrazole alcohol | 浙江工业大学 | 2021-08-03 | — | — | CN | claimed |
| CN-111057006-A | Preparation method of 1- (4-chlorphenyl) -3-pyrazole alcohol | 浙江工业大学 | 2020-04-24 | — | — | CN | claimed |
| US-12624024-B2 | EP2 antagonist compounds | RESERVOIR NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3697774-B1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMA (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-16 | — | — | US | disclosed |
| CN-116283778-B | Pyrazolecarboxylic acid compound as well as preparation method and application thereof | 江苏理工学院 | 2025-08-29 | — | — | CN | disclosed |
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| US-12122788-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| EP-1457490-A1 | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity | Takeda Chemical Industries, Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1445254-A1 | PROCESS FOR PRODUCTION OF PYRAZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-08-11 | — | — | EP | disclosed |
| EP-1228067-B1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1394154-A1 | FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | STEINMEYER ANDREAS (US) | 2003-08-07 | — | — | US | disclosed |
| US-6603031-B1 | Active metabolites of vitamin D2 and vitamin D3 and their synthetic derivatives have a proliferation- inhibiting and differentiation-stimulating action on tumor cells and normal cells, | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-1228067-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGYLCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001038325-A1 | 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | CYP24A1, CYP2R1, VDR | KMT2A 4855/4885MEN1 1811/4885TSHR 634/4885 |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | KMT2A 3014/4885MEN1 1794/4885TSHR 1602/4885 |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | SLC5A1, AHR, ALOX5 | KMT2A 1788/4885MEN1 1753/4885TSHR 2362/4885 |
| US-12624024-B2 | EP2 antagonist compounds | PTGER1, PTGER2, PTGER4 | KMT2A 2217/4885MEN1 3479/4885TSHR 657/4885 |
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | KMT2A 3308/4885MEN1 4213/4885TSHR 3890/4885 |
| US-12122788-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | KMT2A 4522/4885MEN1 2440/4885TSHR 2184/4885 |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | KMT2A 4813/4885MEN1 4316/4885TSHR 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.